New Treatment for Alzheimer's Disease, Kamikihito, Reverses Amyloid-β-Induced Progression of Tau Phosphorylation and Axonal Atrophy. This evidence concerns the gene MAPT and early-onset autosomal dominant Alzheimer disease.